Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib in Recurrent Glioblastoma
NCT01112527Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2010
- Primary completion
- Sep 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of dacomitinib in glioblastoma (GBM) (3 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Apr 2010; status: completed.
02
Drugs
dacomitinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT01112527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01112527.